LYMPHOMAS

Patients with Waldenström macroglobulinemia experience comparable outcomes when switching from ibrutinib to zanubrutinib, with improved safety profiles.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.

Pirtobrutinib shows significant efficacy and safety in treating relapsed/refractory follicular lymphoma, with promising response rates and durable outcomes.

Duvelisib is now a recommended treatment for cutaneous T-cell lymphoma, highlighting its evolving role in oncology amidst safety concerns.

Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of CAR T-cell therapy.

The FDA reviews nivolumab with chemotherapy as a potential new frontline treatment for advanced classical Hodgkin lymphoma, promising improved outcomes.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

FDA and EMA approve AVC-203, a groundbreaking CAR-T therapy targeting B-cell malignancies, promising enhanced safety and scalability for patients.

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel.

Dexamethasone prophylaxis significantly reduces severe neurotoxicity in LBCL patients receiving axi-cel, enhancing safety without compromising efficacy.

Sonrotoclax shows promising efficacy and tolerability in treating relapsed mantle cell lymphoma, with ongoing trials to confirm its potential.

Circulating tumor DNA (ctDNA) emerges as a crucial prognostic tool for lymphoma, enhancing event-free survival predictions and treatment response insights.

A novel treatment regimen for high-risk mantle cell lymphoma shows impressive response rates and minimal residual disease in early trial results.

A phase 2 study reveals promising results for zanubrutinib combined with R-CHOP in treating untreated diffuse large B-cell lymphoma patients.

GLPG5101 shows promising efficacy and safety in treating relapsed/refractory non-Hodgkin lymphoma, achieving high response rates and rapid manufacturing.

A targeted therapy-first approach shows promise in reducing chemotherapy needs for newly diagnosed large B-cell lymphoma patients, maintaining high response rates.

Epcoritamab combined with rituximab and lenalidomide shows remarkable efficacy in treating relapsed follicular lymphoma, setting a new standard of care.

Epcoritamab combined with R-mini-CHOP shows promising efficacy and safety in elderly DLBCL patients, achieving high response rates and durable remissions.

Odronextamab shows promising efficacy in treating untreated DLBCL, achieving high response rates when combined with CHOP chemotherapy in early trials.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

Sonrotoclax gains FDA priority review for relapsed mantle cell lymphoma, showcasing promising efficacy and safety in challenging patient populations.

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.